Pulmonary sarcomatoid carcinoma presenting both ALK rearrangement and PD-L1 high positivity: A case report on the therapeutic regimen.
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Aug 2019
Aug 2019
Historique:
entrez:
9
8
2019
pubmed:
9
8
2019
medline:
4
9
2019
Statut:
ppublish
Résumé
Pulmonary sarcomatoid carcinoma (PSC) represents <1% of all lung cancers and is characterized by a very poor prognosis. The optimal therapeutic regimen remains unclear. We describe a rare case of PSC with both anaplastic lymphoma kinase (ALK)-arranged and high levels of programmed death ligand 1 (PD-L1) expression. A 46-year-old woman, nonsmoker, came to our attention due to uncontrolled pain in the lower left limb. PSC with both ALK rearrangement and high levels of PD-L1 expression. The patient started first-line systemic treatment with pembrolizumab reporting stable disease; at progression, she received second-line treatment with crizotinib. The treatment was not well-tolerated, and the patient then underwent 5 cycles of ceritinib treatment. The patient showed a partial response to targeted therapy. At progression, brigatinib was initiated, but the patients reported liver progression soon after the initiation of this therapy. Molecular-driven investigation is necessary in PSC for treatment selection.
Identifiants
pubmed: 31393391
doi: 10.1097/MD.0000000000016754
pii: 00005792-201908090-00051
pmc: PMC6708868
doi:
Substances chimiques
Antineoplastic Agents
0
B7-H1 Antigen
0
Anaplastic Lymphoma Kinase
EC 2.7.10.1
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e16754Références
Yendamuri S, Caty L, Pine M, et al. Outcomes of sarcomatoid carcinoma of the lung: a surveillance, epidemiology, and end results database analysis. Surgery 2012;152:397–402.
Vieira T, Antoine M, Hamard C, et al. Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophages. Lung Cancer 2016;98:51–8.
Kim S, Kim MY, Koh J, et al. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas. Eur J Cancer 2015;51:2698–707.
Pelosi G, Gasparini P, Cavazza A, et al. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer 2012;77:507–14.
Ghobrial FE, Eldin MS, Razek AAKA, et al. Computed tomography assessment of hepatic metastases of breast cancer with revised response evaluation criteria in solid tumors (RECIST) criteria (Version 1.1): inter-observer agreement. Pol J Radiol 2017;82:593–7.
Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:e143–52.
Lin K, Cheng J, Yang T, et al. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB. Biochem Biophys Res Commun 2015;463:95–101.
Li D, Zhu X, Li N, et al. Correlation of PD-L1 expression with EGFR, KRAS, or ALK alterations and with survival of non-small cell lung cancer (NSCLC) treated with EGFR-TKIs: a meta-analysis of published trials. J Clin Oncol 2016;34: DOI: 10.1200/JCO.2016.34.15_suppl.e20576.
doi: 10.1200/jco.2016.34.15_suppl.e20576
Ripault MP, Pinzani V, Fayolle V, et al. Crizotinib-induced acute hepatitis: first case with relapse after reintroduction with reduced dose. Clin Res Hepatol Gastroenterol 2013;37:e21–3.
Sassier M, Mennecierc B, Gschwendc A, et al. Successful treatment with ceritinib after crizotinib induced hepatitis. Lung Cancer 2016;95:15–6.
Ota K, Azuma K, Kawahara A, et al. Induction of PD-L1 expression by the EML4–ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res 2015;21:4014–21.
Hong S, Chen N, Fang W, et al. Upregulation of PD-L1 by EML4–ALK fusion protein mediates the immune escape in ALK positive NSCLC: implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. Oncoimmunology 2016;5:e1094598.